Mur­al On­col­o­gy spins out from Alk­er­mes with $275M and a lead im­munother­a­py pro­gram

Mur­al On­col­o­gy is spin­ning out of Alk­er­mes with $275 mil­lion and a lead im­munother­a­py can­di­date al­ready in two stud­ies in mu­cos­al melanoma and ovar­i­an can­cer.

On top of the fund­ing, Alk­er­mes is al­so dis­trib­ut­ing Mur­al stock to its share­hold­ers — one Mur­al share for every 10 Alk­er­mes shares they own.

The com­pa­ny will start trad­ing on the Nas­daq on Nov. 16 un­der $MU­RA. Its lead drug, an in­ter­leukin-2 (IL-2) cy­tokine dubbed nem­valeukin al­fa, is al­ready in two reg­is­tra­tional stud­ies in mu­cos­al melanoma as a monother­a­py and an­oth­er for plat­inum-re­sis­tant ovar­i­an can­cer in com­bi­na­tion with pem­brolizum­ab (Keytru­da). Topline da­ta are ex­pect­ed for both in the first quar­ter of 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER